Accelerated atherosclerosis in systemic lupus erythematosus and other connective tissue diseases

References

• Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal pattern of systemic lupus erythematosus. Am. J. Med.60, 221–225 (1976).
   PubMed Web of Science ®Google Scholar
• Manzi S, Meilahn EN, Rairie JE et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am. J. Epidemiol.145, 408–415 (1997).
   PubMed Web of Science ®Google Scholar
• Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum.42, 338–346 (1999).
   PubMed Web of Science ®Google Scholar
• Esdaile JM, Abrahamowicz M, Grodzicky T et al. Traditional Framingham risk factors fail to account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum.44, 2331–2337 (2001).
   PubMed Web of Science ®Google Scholar
• Hall FC, Dalbeth N. Disease modification and cardiovascular risk reduction: two sides of the same coin? Rheumatology44, 1473–1482 (2005).
   PubMedGoogle Scholar
• Rhew EY, Ramsey-Goldman R. Premature atherosclerotic disease in systemic lupus erythematosus – role of inflammatory mechanism. Autoimmunity Rev.5, 101–105 (2006).
   PubMed Web of Science ®Google Scholar
• Ames PR, Alves J, Murat I, Isenberg DA, Nourooz-Zadeh J. Oxidative stress in systemic lupus erythematosus and allied conditions with vascular involvement. Rheumatology38, 529–534 (1999).
   PubMed Web of Science ®Google Scholar
• Morgan PE, Sturgess AD, Davies MJ. Increased levels of serum protein oxidation and correlation with disease activity in systemic lupus erythematosus. Arthritis Rheum.52, 2069–2079 (2005).
   PubMed Web of Science ®Google Scholar
• Frostegard J, Svenungson E, Wu R et al. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum.52, 192–200 (2005).
   PubMed Web of Science ®Google Scholar
• Tso T, Huang W, Huang HY, Chang CK. Relationship of plasma interleukin-18 concentrations to traditional and non-traditional cardiovascular risk factors in patients with systemic lupus erythematosus. Rheumatology45, 1148–1153 (2006).
   PubMed Web of Science ®Google Scholar
• Memon RA, Staprans I, Noor M et al. Infection and inflammation induce LDL oxidation in vivo. Arterioscler. Thromb. Vasc. Biol.20, 1536–1542 (2000).
   PubMed Web of Science ®Google Scholar
• Matsuura E, Kobayashi K, Koike T, Shoenfeld Y. Autoantibody-mediated atherosclerosis. Autoimmunity Rev.1, 348–353 (2002).
   PubMedGoogle Scholar
• Kobayashi K, Kishi M, Atsumi T et al. Circulating oxidized LDL forms complexes with β2-glycoprotein I: implication as an atherogenic autoantigen. J. Lipid Res.44, 716–726 (2003).
   PubMed Web of Science ®Google Scholar
• Liu Q, Kobayashi K, Furukawa J et al. ω-carboxyl variants of 7-ketocholesteryl esters are ligands for β2-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages. J. Lipid Res.43, 1486–1495 (2002).
   PubMed Web of Science ®Google Scholar
• Matsuura E, Kobayashi K, Tabuchi M, Lopez LR. Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis. Prog. Lipid Res.45, 466–486 (2006).
   PubMedGoogle Scholar
• Matsuura E, Kobayashi K, Hurley BL, Lopez LR. Atherogenic oxidized low-density lipoprotein/β2-glycoprotein I (oxLDL/β2GPI) complexes in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus15, 478–483 (2006).
   PubMed Web of Science ®Google Scholar
• Lopez LR, Simpson DF, Hurley BL, Matsuura E. OxLDL/β2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid sindrome: pathogenic implications for vascular involvement. Ann. NY Acad. Sci.1051, 313–322 (2005).
   PubMedGoogle Scholar
• Farzaneh-Far A, Roman MJ, Lockshin MD et al. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum.54, 3918–3925 (2006).
   PubMed Web of Science ®Google Scholar
• Amoroso A, Cacciapaglia F, De Castro S et al. The adjunctive role of antiphospholipid antibodies in systemic lupus erythematosus cardiac involvement. Clin. Exp. Rheumatol.24, 287–294 (2006).
   PubMedGoogle Scholar
• Shoenfeld Y, Wu R, Dearing L, Matsuura E. Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective?. Circulation110, 2552–2558 (2004).
   Google Scholar
• Sherer Y, Shoenfeld Y. Mechanism of disease: atherosclerosis in autoimmune diseases. Nat. Clin. Pract. Rheumatol.2, 99–106 (2006).
   PubMedGoogle Scholar
• Asanuma Y, Chung CP, Oeser A et al. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J. Rheumatol.33, 539–545 (2006).
   PubMed Web of Science ®Google Scholar
• Jackson M, Ahmad Y, Bruce I, Coupes B, Brenchley P. Activation of transforming growth factor-β1 and early atherosclerosis in systemic lupus erythematosus. Arthritis Res. Ther.8, R81 (2006).
   Google Scholar
• McMahon M, Grossman J, FitzGerald J et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum.54, 2541–2549 (2006).
   PubMed Web of Science ®Google Scholar
• Kiss E, Soltesz P, Der H et al. Reduced flow-mediated vasodilatation as a marker for cardiovascular complications in lupus patients. J. Autoimmunity27, 211–217 (2006).
   PubMed Web of Science ®Google Scholar
• Wright SA, O’Prey FM, Rea DJ et al. Microcirculatory hemodynamics and endothelial dysfunction in systemic lupus erythematosus. Arterioscler. Thromb. Vasc. Biol.26, 2281–2287 (2006).
   PubMed Web of Science ®Google Scholar
• Svenungsson E, Jensen-Urstad K, Heimbürger M et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation104, 1887–1893 (2001).
   PubMed Web of Science ®Google Scholar
• Gerli R, Schillaci G, Giordano A et al. CD4+CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation109, 2744–2278 (2004).
   PubMed Web of Science ®Google Scholar
• Sherer Y, Gerli R, Gliburd B et al. Thickened carotid artery intima-media in rheumatoid arthritis is associated with elevated anticardiolipin antibodies. Lupus16, 259–264 (2007).
   PubMedGoogle Scholar
• Gerli R, Sherer Y, Bartoloni Bocci E, Vaudo G, Moscatelli S, Shoenfeld Y. Precocious atherosclerosis in rheumatoid arthritis: role of traditional and disease-related cardiovascular risk factors. Ann. NY Acad. Sci. (2007) (In press).
   Google Scholar
• Selzer F, Sutton-Tyrrell K, Fitzgerald S, Tracy R, Kuller L, Manzi S. Vascular stiffness in women with systemic lupus erythematosus. Hypertension37, 1075–1082 (2001).
   PubMed Web of Science ®Google Scholar
• Selzer F, Sutton-Tyrrell K, Fitzgerald S et al. Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum.50, 151–159 (2004).
   PubMed Web of Science ®Google Scholar
• Asanuma Y, Oeser A Shintani A et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med.349, 2407–2415 (2003).
   PubMed Web of Science ®Google Scholar
• Von Feldt J, Scalzi L, Cucchiara A et al. Homocysteine levels and disease duration independently correlate with coronary artery calcifications in patients with systemic lupus erythematosus. Arthritis Rheum.54, 2220–2227 (2006).
   PubMed Web of Science ®Google Scholar
• Frostegård J. Atherosclerosis in patients with autoimmune disorders. Arterioscler. Thromb. Vasc. Biol.25, 1776–1785 (2005).
   PubMed Web of Science ®Google Scholar
• Bruce IN. “Not only…but also”: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology44, 1492–1502 (2005).
   PubMed Web of Science ®Google Scholar
• Petri M, Spence D, Bone LR, Hochberg MC. Coronary artery disease risk factors in the Johns Hopkins lupus cohort: prevalence recognition by patients and preventive practise. Medicine71, 291–302 (1992).
   PubMed Web of Science ®Google Scholar
• Bessant R, Duncan R, Ambler G, Swanton J, Isenberg D, Rahman A. Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: a case–control study. Arthritis Care Res.55, 892–899 (2006).
   Google Scholar
• Toloza SM, Uribe AG, McGwin G et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). Baseline predictors of vascular events. Arthritis Rheum.50, 3947–3957 (2004).
   PubMed Web of Science ®Google Scholar
• Bessant R, Hingorani A, Patel L, MacGregor A, Isenberg DA, Rahman A. Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology43, 924–929 (2004).
   PubMed Web of Science ®Google Scholar
• Doria A, Shoenfeld Y, Wu R et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann. Rheum. Dis.62, 1071–1077 (2003).
   PubMed Web of Science ®Google Scholar
• Roman MJ, Shanker B, Davis A et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med.349, 2399–2406 (2003).
   PubMed Web of Science ®Google Scholar
• Sarkissian T, Beyene J, Feldman B, McCrindle B, Silverman E. Longitudinal examination of lipid profiles in pediatric systemic lupus erythematosus. Arthritis Rheum.56, 631–638 (2007).
   PubMedGoogle Scholar
• Escàrcega R, Garcìa-Carrasco M, Fuentes-Alexandro S et al. Insulin resistance, chronic inflammatory state and the link with systemic lupus erythematosus-related coronary disease. Autoimmunity Rev.6, 48–53 (2006).
   PubMed Web of Science ®Google Scholar
• El-Magadmi M, Ahmad Y, Turkic W et al. Hyperinsulinaemia, insulin resistance and circulating oxidised low density lipoprotein in women with systemic lupus erythematosus. J. Rheumatol.33, 50–56 (2006).
   PubMedGoogle Scholar
• Chung CP, Avalos I, Oeser A et al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann. Rheum. Dis.66, 208–214 (2007).
   PubMed Web of Science ®Google Scholar
• Maksimowicz-McKinnon K, Madger L, Petri M. Predictors of carotid atherosclerosis in systemic lupus erythematosus. J. Rheumatol.33, 2458–2463 (2006).
   PubMed Web of Science ®Google Scholar
• Manger K, Kusus M, Forster C et al. Factors associated with coronary artery calcification in young female patients with SLE. Ann. Rheum. Dis.62, 846–850 (2003).
   PubMed Web of Science ®Google Scholar
• Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ. Res.91, 281–291 (2002).
   PubMed Web of Science ®Google Scholar
• Viedt C, Hansch GM, Brandes RP, Kubler W, Kreuzer J. The terminal complement complex C5b-C9 stimulates interleukin-6 production in human smooth muscle cells through activation of transcription factors NF-κ B and AP-1. FASEB J.14, 2370–2372 (2000).
   PubMedGoogle Scholar
• Grainger D, Bethell HW. High titres of serum antinuclear antibodies, mostly directed against nucleolar antigens, are associated with the presence of coronary atherosclerosis. Ann. Rheum. Dis.61, 110–114 (2002).
   PubMedGoogle Scholar
• Marasini B, De Monti M, Ghilardi G. Risk factors for accelerated atherosclerosis in patients with systemic lupus erythematosus. Ann. Rheum. Dis.64, 163–164 (2005).
   PubMedGoogle Scholar
• Yazdany J, Davis J. The role of CD40 ligand in systemic lupus erythematosus. Lupus13, 377–380 (2004).
   PubMed Web of Science ®Google Scholar
• Vishnevetsky D, Kiyanista VA, Gandhi PJ. CD40 ligand: a novel target in the fight against cardiovascular disease. Ann. Pharmacother.38, 1500–1508 (2004).
   PubMed Web of Science ®Google Scholar
• Nickolas TL, Radhakrishnan J, Appel GB. Hyperlipidemia and thrombotic complications in patients with membranous nephropathy. Semin. Nephrol.23, 406–411 (2003).
   PubMed Web of Science ®Google Scholar
• Borba EF, Bonfa E. Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J. Rheumatol.28, 780–785 (2001).
   PubMed Web of Science ®Google Scholar
• Prowse C, Pepper D, Dawes J. Prevention of the platelet α-granule release reaction by membrane-active drugs. Thromb. Res.25, 219–227 (1982).
   PubMed Web of Science ®Google Scholar
• Espinola RG, Pierangeli SS, Gharavi AE, Harris EN, Ghara AE. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb. Haemostasis87, 518–522 (2002).
   PubMed Web of Science ®Google Scholar
• Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation109S, III27–III32 (2004).
   Google Scholar
• Davignon J, Jacob RF, Mason RP. The antioxidant effect of statins. Coron. Artery Dis.15, 251–258 (2004).
   PubMed Web of Science ®Google Scholar
• Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol.21, 473–480 (2001).
   PubMed Web of Science ®Google Scholar
• Delgado-Alves J, Ames PR, Donohue S et al. Antibodies to high-density lipoprotein and β2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum.46, 2686–2694 (2002).
   PubMedGoogle Scholar
• Balogh Z, Seres I, Harangi M, Kovacs P, Kakuk G, Paragh G. Gemfibrozil increases paraoxonase activity in Type 2 diabetic patients: a new hypothesis of the beneficial action of fibrates? Diabetes Metab.27, 604–610 (2001).
   PubMed Web of Science ®Google Scholar
• Kotyla P, Sliwinska-Kotyla B, Kucharz E. Tumor necrosis factor-α as a potential target in the treatment of systemic lupus erythematosus: a role for the HMG-CoA reductase inhibitor simvastatin. J. Rheumatol.33, 2361 (2005).
   Google Scholar
• Yokota K, Miyazaki T, Hirano M, Akiyama Y, Mitura T. Simvastatin inhibits production of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosis factor α in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J. Rheumatol.33, 463–471 (2006).
   PubMed Web of Science ®Google Scholar
• Matucci-Cerinic M, Fiori G, Grenbaum E, Shoenfeld Y. Macrovascular disease in systemic sclerosis. In: Systemic Sclerosis. Furst D, Clements P (Eds), Lippincott Williams and Wilkins, MD, USA 241 (2003).
   Google Scholar
• Shoenfeld Y, Gerli R, Doria A et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation112, 3337–3347 (2005).
   PubMed Web of Science ®Google Scholar
• Szücs G, Tìmàr O, Szekanecz Z et al. Endothelial dysfunction precedes atherosclerosis in systemic sclerosis – relevance for prevention of vascular complications. Rheumatology46, 759–762 (2007).
   PubMed Web of Science ®Google Scholar
• Borba EF, Borges CT, Bonfa E. Lipoprotein profile in limited systemic sclerosis. Rheumatol. Int.25, 379–383 (2005).
   PubMed Web of Science ®Google Scholar
• Medina G, Casaos D, Jara L et al. Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome. Ann. Rheum. Dis.62, 607–610 (2003).
   PubMed Web of Science ®Google Scholar
• Ames PR, Delgado Alves J, Lopez LR et al. Antibodies against β2-glycoprotein I complexed with an oxidised lipoprotein relate to intima-media thickening of carotid arteries in primary antiphospholipid syndrome. Clin. Dev. Immunol.13, 1–9 (2006).
   PubMedGoogle Scholar
• Ames PR, Margarita A, Delgado Alves J, Tommasino C, Iannaccone L, Brancaccio V. Anticardiolipin antibody titre and plasma homocysteine levels independently predict intima-media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus11, 208–214 (2002).
   PubMed Web of Science ®Google Scholar
• Hojnik M, Gorge J, Ziporen L, Shoenfeld Y. Heart valve involvement (Libman–Sacks endocarditis) in the antiphospholipid syndrome. Circulation93, 1579–1587 (1996).
   PubMed Web of Science ®Google Scholar
• Turiel M, Muzzupappa G, Gottardi B, Crema C, Sarzi-Puttini P, Rossi E. Evaluation of cardiac abnormality and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography. Lupus9, 406–412 (2000).
   PubMed Web of Science ®Google Scholar
• Vaudo G, Bartoloni Bocci E, Shoenfeld Y et al. Precocious intima-media thickening in patients with primary Sjögren’s syndrome. Arthritis Rheum.52, 3890–3897 (2005).
   PubMedGoogle Scholar
• Gerli R, Muscat C, Giansanti M et al. Quantitative assessment of salivary gland inflammatory infiltration in primary Sjögren’s syndrome: its relationship to different demographic, clinical and serological features of the disorder. Br. J. Rheumatol.36, 969–975 (1997).
   PubMedGoogle Scholar
• Lodde BM, Sankar V, Kok MR et al. Serum lipid levels in Sjögren’s syndrome. Rheumatology45, 481–484 (2006).
   PubMed Web of Science ®Google Scholar
• Gerli R, Bartoloni Bocci E, Vaudo G, Marchesi S, Vitali C, Shoenfeld Y. Traditional cardiovascular risk factors in primary Sjögren’s syndrome-role of dyslipidaemia. Rheumatology45, 1581–1582 (2006).
   Google Scholar
• Lopez LR, Salazar-Paramo M, Palafox-Sanchez C et al. Oxidized low-density lipoprotein and β2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness: implications in autoimmune-mediated atherosclerosis. Lupus15, 80–86 (2006).
   PubMed Web of Science ®Google Scholar
• Roman MJ, Salmon ES, Sabel R et al. Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Am. J. Cardiol.87, 663–666 (2001).
   PubMed Web of Science ®Google Scholar
• Lima DS, Sato EI, Lima VC, Mirando F Jr, Hatta FH. Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J. Rheumatol.29, 292–297 (2002).
   PubMed Web of Science ®Google Scholar
• Wolak T, Todosoui E, Szendro G et al. Duplex study of the carotid and femoral arteries of patients with systemic lupus erythematosus: a controlled study. J. Rheumatol.31, 909–914 (2004).
   PubMed Web of Science ®Google Scholar
• Jiménez S, Garcìa-Criado M, Tàssies D et al. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology44, 756–761 (2005).
   PubMedGoogle Scholar
• El-Magadmi M, Bodill H, Ahmad Y et al. Systemic lupus erythematosus. An independent risk factor for endothelial dysfunction in women. Circulation110, 399–404 (2004).
   PubMed Web of Science ®Google Scholar
• De Leeuw K, Freire B, Smit AJ, Bootsma H, Kallenberg CG, Bijl M. Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus. Lupus15, 675–682 (2006).
   PubMed Web of Science ®Google Scholar
• Bhatt SP, Handa R, Gulati G et al. Atherosclerosis in Asian Indians with systemic lupus erythematosus. Scand. J. Rheumatol.35, 128–132 (2006).
   PubMed Web of Science ®Google Scholar
• Sella E, Sato E, Leite W, Oliveira Filho J, Barbieri A. Myocardial perfusion scintigraphy and coronary disease risk factor in systemic lupus erythematosus. Ann. Rheum. Dis.62, 1066–1070 (2003).
   PubMed Web of Science ®Google Scholar
• Bessant R, Hingorani A, Patel L, MacGregor A, Isenberg DA, Rahman A. Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology43, 924–929 (2004).
   PubMed Web of Science ®Google Scholar